FIELD: medicine, in particular methods (variants) for prophylaxis and treatment of disorders associated with abnormal lipid carbohydrate metabolism or circulatory disturbances associated therewith in mammalian.
SUBSTANCE: claimed methods includes administration of pioglytazone or pharmaceutically acceptable salt thereof in combination with at least one member selected from group containing alpha-glucosidase inhibitor, aldose reductase inhibitor, biguanide, statin derivative, squalene, fibrate compound, enhancer of low density lipoprotein catabolism and inhibitor of angiotensine converting enzyme to mammalian. Alternatively method includes administration of pioglytazone or pharmaceutically acceptable salt thereof in combination with enhancer of insulin secretion and/or insulin preparation.
EFFECT: synergic effect in relation to lowering of glucose levels in blood, body mass losses, with decreased amount of side effects.
13 cl, 8 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PREVENTION AND TREATMENT AND RELATED COMPLICATION | 1996 |
|
RU2327455C2 |
| PHARMACEUTICAL COMPOSITION | 1996 |
|
RU2198682C2 |
| PHARMACEUTICAL COMPOSITION | 1996 |
|
RU2323004C2 |
| METHOD FOR PROPHYLAXIS AND TREATMENT, USING ENHANCER FOR INSULIN SENSIBILITY | 1996 |
|
RU2223760C2 |
| PANCREATIC DIABETES DRUG | 2004 |
|
RU2358738C2 |
| PHARMACEUTICAL COMPOSITIONS | 2010 |
|
RU2532330C2 |
| THERAPEUTIC ANTIDIABETIC AGENT | 2006 |
|
RU2438671C2 |
| CONDENSED HETEROCYCLIC DERIVATIVES MEDICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICAL APPLICATION | 2005 |
|
RU2387663C2 |
| APPLICATION OF THIAZOLIDINEDIONES FOR PREVENTION OR ONSET POSTPONEMENT OF INSULIN-INDEPENDENT DIABETES MELLITUS (NIDDM) | 1994 |
|
RU2195282C2 |
| METHOD FOR TREATMENT OF IMPAIRED GLUCOSE TOLERANCE | 2001 |
|
RU2281094C2 |
